BioSenic's Phase 3 Study for Chronic GvHD

BioSenic, a clinical-stage company, is set to attend the GvHgvL Meeting to discuss a Phase 3 study of its oral arsenic trioxide therapy for chronic GvHD. The company plans to enroll about 150 patients across three continents this year. BioSenic's CEO emphasized the potential value of this therapy and highlighted the company's focus on developing products in two tracks: immunomodulatory properties of arsenic trioxide for anti-inflammatory and anti-autoimmune indications and cell therapies for tissue repair technologies.